Company: RGNT
Filing Date: 2025-09-09
Form Type: F-1/A
Source: 0001213900-25-085690
Chunk: 6

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-09
Form: F-1/A
Chunk 6
---
 the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to 140,000 Ordinary Shares following
the consummation of this offering.

Between December 2023 and
January 2024, we entered into the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000 from
certain lenders, including certain related parties. In October 2024, we amended the 2024 Loan Agreements pursuant to which the 2024 Loan
Agreements have been extended until August 31, 2025, and shall bear interest at 8% per annum until maturity commencing as of September
1, 2024. Furthermore, upon the occurrence of a Qualified IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase
such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share
equal to 61,538 Ordinary Shares following the consummation of this offering.

On December 1, 2024, we entered
into the December 2024 Loan Agreement with our Chief Executive Officer, according to which accrued payroll salary owed to him in the
aggregate amount of $117,000 plus VAT was converted into a loan. The loan amount bears interest at an 8% annual rate, and is due upon
the earlier of the consummation of this offering or March 31, 2025. In addition, upon maturity, the Company will pay to our Chief Executive
Officer an aggregate risk premium equal to 30% of the loan amount (or approximately $35,100 plus VAT). If a registration statement for
an initial public offering is made effective no later than March 31, 2025, then the maturity date will be extended to June 30, 2025.
In addition, pursuant to the December 2024 Loan Agreement, upon the consummation of this offering the Company will issue warrants, or
the CEO Loan Warrants, exercisable for a period of three years from the date of the issuance, to purchase such number of Ordinary Shares
equal to two times the respective loan amount divided by 75% of the lowest price per Ordinary Share during the first five trading days
following the consummation of this offering, at an exercise price equal to 75% of the lowest price per Ordinary Share during the first
five trading days following the consummation of this offering. The outstanding